Alnylam Pharmaceuticals Inc. appointed Margaret Hamburg to its board, effective Jan. 10, 2019.
Hamburg currently serves as foreign secretary for the National Academy of Medicine and president-elect of the American Association for the Advancement of Science.
In addition, Alnylam said that John Clarke resigned from the board, also effective Jan. 10, 2019. He is the managing partner of Cardinal Partners, the co-founding venture investor of Alnylam, and has served on the board since the company's founding in 2002 and served as board chairman from 2002 through 2015.
The Cambridge, Mass.-based biotechnology company develops treatments using RNA molecules to inhibit gene expression and translation.